Skip to main content

Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · IEX Real-Time Price · USD
7.94 0.52 (7.01%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap94.30M
Revenue (ttm)81,617
Net Income (ttm)n/a
Shares Out11.88M
EPS (ttm)-1.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,986
Open7.43
Previous Close7.42
Day's Range7.43 - 7.94
52-Week Range7.35 - 17.93
Betan/a
Analystsn/a
Price Target30.00 (+277.8%)
Est. Earnings DateNov 11, 2021

About GANX

Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric r...

IndustryBiotechnology
IPO DateMar 18, 2021
Employees11
Stock ExchangeNASDAQ
Ticker SymbolGANX
Full Company Profile

Financial Performance

In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.

Financial Statements

News

Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

- Conference Dates: September 20 th -23 rd -

2 days ago - GlobeNewsWire

Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...

1 week ago - GlobeNewsWire

Why Gain Therapeutics Shares Are Trading Higher Today

Gain Therapeutics Inc (NASDAQ: GANX) are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher a...

1 week ago - Benzinga

Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study

The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (...

1 week ago - Benzinga

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...

GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and dec...

1 week ago - GlobeNewsWire

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...

GT-02287and GT-02329 compounds display positive effects on GCase activity  and related parameters ---  Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and d...

1 week ago - GlobeNewsWire

Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...

2 weeks ago - GlobeNewsWire

Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathie...

1 month ago - GlobeNewsWire

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel alloste...

1 month ago - GlobeNewsWire

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment o...

Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lys...

3 months ago - GlobeNewsWire

Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference

BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...

3 months ago - GlobeNewsWire

Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...

4 months ago - GlobeNewsWire

Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...

4 months ago - GlobeNewsWire

Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds...

Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model

4 months ago - GlobeNewsWire

Gain Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference

BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bi...

4 months ago - GlobeNewsWire

Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 ...

Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selecte...

4 months ago - GlobeNewsWire

Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals

Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously  difficult-to-drug oncology targets

4 months ago - GlobeNewsWire

Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Optio...

BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of...

5 months ago - GlobeNewsWire

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

5 months ago - Benzinga

Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock

Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of...

6 months ago - GlobeNewswire

Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering

Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial...

6 months ago - GlobeNewswire

Lysosomal storage disorder biotech Gain Therapeutics files for a $40 million IPO

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.

6 months ago - NASDAQ

Gain Therapeutics IPO Registration Document (S-1)

Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC